Format

Send to

Choose Destination
An Bras Dermatol. 2018 Mar;93(2):299-301. doi: 10.1590/abd1806-4841.20187162.

Diphencyprone as a therapeutic option in cutaneous metastasis of melanoma. A single-institution experience.

Author information

1
Skin Cancer Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil, Brazil.
2
Oncology Residency Training Program, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
3
Department of Pathology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.

Abstract

Diphencyprone has been reported as a local immunotherapy for cutaneous melanoma metastases. We aim to report cases of melanoma patients treated with diphencyprone in a single Brazilian institution and highlight their outcomes. Since 2012, we have treated 16 melanoma patients with cutaneous metastases with topical diphencyprone. To date, we have had 37.5% of complete response, 25% of partial responses, and 31.25% patients without any response. Treatment was well tolerated and local toxicity was easily controlled. We believe topical diphencyprone is a feasible treatment that can be another option for treating melanoma patients, especially in cases of in-transit or extensive disease.

PMID:
29723355
PMCID:
PMC5916415
DOI:
10.1590/abd1806-4841.20187162
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Scientific Electronic Library Online Icon for PubMed Central
Loading ...
Support Center